Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Toxicity: cardiac toxicity (any grade) · treatment of relapsed epithelial ovarian cancer
EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in toxicity: cardiac toxicity (any grade) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · newly‐diagnosed EOC
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · newly‐diagnosed EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Health status and quality of life · people with advanced gastric cancer
1 finding from 1 review
Overall response rate Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall response rate Duration of compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (any) Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher adverse event (any) Duration of compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Severe adverse event (grade ≥ 3 ) Duration of · people with advanced gastric cancer
Summary of findings: Molecular‐targeted therapy plus chemotherapy probably leads to higher severe adverse event (grade ≥ 3 ) Duration of compared with chemotherapy alone (moderate certainty).
1 finding from 1 review